
    
      This will be a 3-part study with each part being an open-label, fixed sequence, 2-treatment
      study in healthy adult subjects. Part 1, Part 2 and Part 3 may be conducted concurrently or
      separately and the order of the parts may be determined accordingly to the needs of the
      ACH-0144471 development program. A total of 12 subjects will participate in each study part.
    
  